Newer HMG-CoA reductase inhibitor (statin) therapies.
Although most patients can achieve their National Cholesterol Education Program goal with a reduction of < or =30% in low-density lipoprotein cholesterol (LDL-C) levels available with all statins, some patients need greater LDL-C lowering. Furthermore, new study data suggest that greater clinical event reduction may be obtained with more aggressive LDL-C lowering and/or with treatment of factors beyond LDL-C. New formulations of statins. including extended-release preparations, are achieving greater reductions in LDL-C levels as well as favorable modification of high-density lipoprotein cholesterol and triglyceride concentrations while maintaining an excellent safety profile.
Brinton
E A
EA
University of Arizona College of Medicine, Tucson, USA. eliot.brinton@med.va.gov
D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood*; D005229:Fatty Acids, Monounsaturated / Q000627:therapeutic use; D000077340:Fluvastatin; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D007211:Indoles / Q000627:therapeutic use; D011725:Pyridines / Q000627:therapeutic use; D014280:Triglycerides / Q000097:blood
D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D005229:Fatty Acids, Monounsaturated; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007211:Indoles; D011725:Pyridines; D014280:Triglycerides; D000077340:Fluvastatin; C086276:cerivastatin